首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   76543篇
  免费   8586篇
  国内免费   322篇
耳鼻咽喉   722篇
儿科学   1759篇
妇产科学   3024篇
基础医学   8443篇
口腔科学   1751篇
临床医学   21156篇
内科学   14547篇
皮肤病学   947篇
神经病学   6276篇
特种医学   2162篇
外科学   8516篇
综合类   404篇
一般理论   46篇
预防医学   5629篇
眼科学   958篇
药学   4004篇
  1篇
中国医学   63篇
肿瘤学   5043篇
  2023年   1077篇
  2022年   627篇
  2021年   1425篇
  2020年   1423篇
  2019年   1268篇
  2018年   2358篇
  2017年   2484篇
  2016年   2753篇
  2015年   2873篇
  2014年   3351篇
  2013年   4461篇
  2012年   4454篇
  2011年   4937篇
  2010年   3551篇
  2009年   3647篇
  2008年   4206篇
  2007年   4477篇
  2006年   4058篇
  2005年   4004篇
  2004年   3688篇
  2003年   3384篇
  2002年   3101篇
  2001年   1133篇
  2000年   831篇
  1999年   1106篇
  1998年   1223篇
  1997年   1216篇
  1996年   1118篇
  1995年   985篇
  1994年   775篇
  1993年   712篇
  1992年   650篇
  1991年   619篇
  1990年   624篇
  1989年   584篇
  1988年   512篇
  1987年   474篇
  1986年   446篇
  1985年   518篇
  1984年   402篇
  1983年   365篇
  1982年   348篇
  1981年   309篇
  1980年   252篇
  1979年   302篇
  1978年   267篇
  1977年   283篇
  1976年   208篇
  1975年   219篇
  1972年   200篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Die Anaesthesiologie - Phantomschmerzen haben eine hohe Prävalenz nach Majoramputationen und sind mit einer zusätzlichen Einschränkung der Lebensqualität verbunden....  相似文献   
2.
3.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
4.
Introduction: The Hedgehog (HH) pathway constitutes a collection of signaling molecules which critically influence embryogenesis. In adults, however, the HH pathway remains integral to the proliferation, maintenance, and apoptosis of adult stem cells including hematopoietic stem cells.

Areas covered: We discuss the current understanding of the HH pathway as it relates to normal hematopoiesis, the pathology of acute myeloid leukemia (AML), the rationale for and data from combination therapies including HH pathway inhibitors, and ultimately the prospects that might offer promise in targeting this pathway in AML.

Expert opinion: Efforts to target the HH pathway have been focused on impeding this disposition and restoring chemosensitivity to conventional myeloid neoplasm therapies. The year 2018 saw the first approval of a HH pathway inhibitor (glasdegib) for AML, though for an older population and in combination with an uncommonly-used therapy. Several other clinical trials with agents targeting modulators of HH signaling in AML and MDS are underway. Further study and understanding of the interplay between the numerous aspects of HH signaling and how it relates to the augmented survival of AML will provide a more reliable substrate for therapeutic strategies in patients with this poor-risk disease.  相似文献   

5.
Despite common experiences of identity damage, decline, and deterioration, many brain injury survivors succeed in reconstructing robust identities in the wake of injury. Yet, while this accomplishment greatly benefits survivors’ quality of life, little is known about how positive identity work might be facilitated or enhanced in therapeutic institutions. Drawing on data from a women’s self-help group, we argue that an egalitarian, reflective, strength-focused, and gender-segregated environment can provide female ABI (acquired brain injury) survivors with a fertile scene for identity enhancement and offer unique opportunities for collective identity development. Sociolinguistic interactional analysis revealed four types of positive identity work undertaken within the group: constructing competent selves; tempering the threat of loss and impairment; resisting infantilisation and delegitimisation; and asserting a collective gender identity. This identity work was facilitated by specific programme attributes and activities and contributed to the global project of decentring disability and destigmatising impairments and losses. We call for increased attention to identity issues in brain injury rehabilitation and argue that gender-segregated programming can provide a unique space for female survivors to construct empowering individual and collective identities after injury.  相似文献   
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号